Description
Key facts
Cell type:HEK-293T,
Species or organism:Human,
Tissue:Kidney,
Knockout validation:Sanger Sequencing,
Mutation description:Knockout achieved by using CRISPR/Cas9, Homozygous: Insertion of the selection cassette in exon 1.
Product details:
Knockout cell lysate achieved by CRISPR/Cas9.
REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation:
Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10).
This means that the protein of interest is denatured.
If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions:
Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our
limited use license
patent pages
Properties and Storage Information:
Gene name-CSTB, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Sanger Sequencing, Zygosity-Homozygous, Shipped at conditions-Ambient - Can Ship with Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions--20°C
Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
Cystatin-B also known as STEFIN-B is a protease inhibitor with a molecular mass of approximately 11 kilodaltons. It belongs to the family of cystatins which are expressed widely in human tissues with notable presence in the brain liver and kidneys. Cystatin-B acts by inhibiting cysteine proteases preventing them from degrading proteins indiscriminately. The inhibition is important for maintaining cellular protein balance and integrity.
Biological function summary
Cysteine protease inhibition by Cystatin-B protects cells from uncontrolled proteolysis which can lead to tissue damage. This protein plays an important role in the regulation of various cellular processes including apoptosis phagocytosis and the response to oxidative stress. It does not form part of a larger complex but interacts directly with its target proteases to exert its inhibitory effects.
Pathways
Cystatin-B influences proteolytic pathways by modulating the activity of cysteine proteases such as cathepsins. By inhibiting these enzymes Cystatin-B participates in the regulation of the lysosomal degradation pathway and apoptotic pathways which are important for cellular turnover and programmed cell death. Cathepsins particularly cathepsin B and L are related proteins that are significantly modulated through their interaction with Cystatin-B.
Mutations or dysregulation of Cystatin-B are associated with progressive myoclonus epilepsy and certain neurodegenerative diseases. The lack of functional Cystatin-B leads to excessive activity of proteases like cathepsin B resulting in increased proteolysis and neuronal damage. In some cases this can also connect to disorders involving oxidative stress exacerbating the detrimental cycle of cellular injury.
